Clinical Trials
22 trialsNCT04439292 2026-06-02
Testing Trametinib and Dabrafenib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol H)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT03149029 2026-04-21
Abbreviated MAPK Targeted Therapy Plus Pembrolizumab in Melanoma
Massachusetts General Hospital
Phase 2 Active not recruiting
NCT04452877 2026-01-13
A Study of Dabrafenib in Combination With Trametinib in Chinese Patients With BRAF V600E Mutant Metastatic NSCLC
Novartis
Phase 2 Completed
NCT01723202 2025-08-24
Dabrafenib With or Without Trametinib in Treating Patients With Advanced Differentiated Thyroid Cancer
Ohio State University Comprehensive Cancer Center
Phase 2 Completed
NCT04310397 2024-10-30
Dabrafenib, Trametinib, and Spartalizumab for the Treatment of BRAF V600E or V600K Mutation Positive Stage IIIB/C/D Melanoma
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT02367859 2024-01-30
Dabrafenib and Trametinib in Treating Patients With BRAF Mutated Ameloblastoma
Stanford University
Phase 2 Completed
NCT02684058 2023-12-13
Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors
Novartis
Phase 2 Completed
NCT02034110 2023-08-21
Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers
Novartis
Phase 2 Completed
NCT01336634 2022-04-04
Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination With Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer.
Novartis
Phase 2 Completed
NCT02083354 2022-02-01
Study to Investigate the Objective Response Rate of Dabrafenib in Combination With Trametinib in Subjects With BRAF V600 Mutation-Positive Melanoma
Novartis
Phase 2 Completed
NCT02974803 2021-08-20
Concurrent Dabrafenib + Trametinib With Sterotactic Radiation in BRAF Mutation-Positive Malignant Melanoma and Brain Metastases
Canadian Cancer Trials Group
Phase 2 Terminated
NCT01682213 2020-05-26
Adjuvant Dabrafenib (GSK2118436) in Patients With Surgically Resected AJCC Stage IIIC Melanoma Characterized by a BRAFV600E/K Mutation
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT01072175 2019-07-05
Investigate Safety, Pharmacokinetics and Pharmacodynamics of GSK2118436 & GSK1120212
Novartis
Phase 2 Completed
NCT02039947 2019-05-21
Study to Evaluate Treatment of Dabrafenib Plus Trametinib in Subjects With BRAF Mutation-Positive Melanoma That Has Metastasized to the Brain
Novartis
Phase 2 Completed
NCT02314143 2019-02-18
Phase II Biomarker Study Comparing the Combination of BRAF Inhibitor Dabrafenib With MEK Inhibitor Trametinib Versus the Combination After Monotherapy With Dabrafenib or Trametinib
GlaxoSmithKline
Phase 2 Terminated
NCT01978236 2018-08-17
Dabrafenib/Trametinib, BRAF or BRAF AND MEK Pre-op With BRAF and MEK Post-op, Phase IIB, Melanoma With Brain Mets,Biomarkers and Metabolites
GlaxoSmithKline
Phase 2 Terminated
NCT01721603 2018-01-23
Dabrafenib and Trametinib With Radiosurgery in Melanoma Brain Mets
University of California, San Francisco
Phase 2 Terminated
NCT01153763 2017-09-27
A Study of GSK2118436 in BRAF Mutant Metastatic Melanoma
GlaxoSmithKline
Phase 2 Completed
NCT01928940 2017-07-24
Japan PhI/II of GSK2118436 and GSK1120212 Combination in Subjects With BRAF V600E/K Mutation Positive Advanced Solid Tumors (Phase I Part) or Cutaneous Melanoma (Phase II Part)
GlaxoSmithKline
Phase 2 Completed
NCT01701037 2017-06-23
Dabrafenib Alone and in Combination With Trametinib Before Surgery in Treating Patients With Locally or Regionally Advanced Melanoma That Can Be Removed By Surgery
Vanderbilt-Ingram Cancer Center
Phase 2 Terminated
NCT01619774 2016-12-12
An Open-Label Phase II Study of the Combination of GSK2118436 and GSK1120212 in Patients With Metastatic Melanoma Which is Refractory or Resistant to BRAF Inhibitor
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01266967 2014-05-08
Break MB
GlaxoSmithKline
Phase 2 Completed